FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Thomas Thomas T. 2. Issuer Name and Ticker or Trading Symbol OPIANT PHARMACEUTICALS, INC. [ OPNT ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)         (First)         (Middle)
C/O OPIANT PHARMACEUTICALS, INC., 233 WILSHIRE BLVD. SUITE 280
3. Date of Earliest Transaction (MM/DD/YYYY)
9/14/2021
(Street)
SANTA MONICA, CA 90401
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  9/14/2021    M    25  A $10  6678  D   
Common Stock  9/14/2021    S(1)    15 (2) D $18.95  6663  D   
Common Stock  9/14/2021    M    1500  A $10  8163  D   
Common Stock  9/14/2021    S(1)    792 (3) D $19.06  7371  D   
Common Stock  9/14/2021    M    1500  A $10  8871  D   
Common Stock  9/14/2021    S(1)    764 (4) D $19.70  8107  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy)  $10.0  9/14/2021    M (5)       25    (6) 11/3/2021  Common Stock  25.0  $0  6834  D   
Stock Option (right to buy)  $10.0  9/14/2021    M (5)       1500    (6) 11/3/2021  Common Stock  1500.0  $0  5334  D   
Stock Option (right to buy)  $10.0  9/14/2021    M (5)       1500    (6) 11/3/2021  Common Stock  1500.0  $0  3834  D   

Explanation of Responses:
(1)  The shares were sold pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.
(2)  The shares were sold to cover the $10 exercise price of the vested stock options. The net shares of 10, after selling to cover the exercise price, will be held by the Reporting Person.
(3)  The shares were sold to cover the $10 exercise price of the vested stock options. The net shares of 708, after selling to cover the exercise price, will be held by the Reporting Person.
(4)  The shares were sold to cover the $10 exercise price of the vested stock options. The net shares of 736, after selling to cover the exercise price, will be held by the Reporting Person.
(5)  The option was exercised pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.
(6)  On November 4, 2016, the reporting person was granted an option to purchase 35,000 shares of Common Stock. The options vest as follows: (i) 11,667 share upon the up listing of the Issuer to The NASDAQ Stock Market (which occurred on August 29, 2017); (ii) 11,667 shares upon the cumulative funding of the Issuer in excess of $5,000,000 by institutional investors, commencing May 5, 2016 (which performance criteria was met on December 13, 2016); and (iii) 11,666 shares upon the first submission of a New Drug Application ("NDA") to the FDA for one of Issuer's products by either the Issuer or an Issuer licensee.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Thomas Thomas T.
C/O OPIANT PHARMACEUTICALS, INC.
233 WILSHIRE BLVD. SUITE 280
SANTA MONICA, CA 90401
X



Signatures
/s/ Thomas T. Thomas 9/16/2021
**Signature of Reporting Person Date
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
From Sep 2021 to Oct 2021 Click Here for more Opiant Pharmaceuticals Charts.
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
From Oct 2020 to Oct 2021 Click Here for more Opiant Pharmaceuticals Charts.